Acadia Healthcare Jumps 100% YTD on Improving Outlook and Expansion

Acadia Healthcare shares are up 100% year to date after management raised 2026 adjusted EBITDA and earnings outlook, lifted operating-cash-flow guidance to $350-$400 million from $285-$325 million, and reduced capex guidance to $235-$255 million. The company added 240 licensed beds through two joint-venture facilities in Q2 2026, supporting longer-term capacity growth. Consensus 2026 EPS is $1.55 following four upward revisions in 60 days, while 2026 revenue is projected to rise 3.4% to $3.42 billion; elevated leverage and patient-related litigation costs remain key risks.

Analysis

ACHC’s rerating now depends less on incremental bed openings and more on proving that free-cash-flow conversion is durable after liability costs. Lower capex improves near-term deleveraging capacity, but the market will discount that benefit if patient-litigation reserves, insurance premiums, or settlement cash payments reaccelerate. The key second-order effect is that joint ventures can lower market-entry risk and improve referral density, but they also dilute economics versus wholly owned facilities and may conceal slower organic same-facility growth.

After a 100% YTD move, the next 1-3 month catalyst is not another beat—four recent beats make that increasingly embedded—but evidence that EBITDA guidance can be achieved without relying on favorable reserve development or capex deferral. A negative revision to legal accruals, a deterioration in operating cash flow versus EBITDA, or net leverage failing to decline would likely trigger a sharper selloff than a routine volume miss. Conversely, sustained cash conversion and debt reduction over the next two quarters could support a further multiple normalization despite modest revenue growth.

The contrarian read is that THC offers a cleaner way to express improving provider operating leverage: broader acute-care exposure, higher estimate momentum, and less idiosyncratic behavioral-health liability risk. ENSG is the structural quality alternative, but its higher growth profile can be more exposed to labor-cost or reimbursement disappointments. UNH’s earnings recovery is relevant to payer-provider sentiment, yet it is not a direct read-through to ACHC because behavioral-health reimbursement and facility-level utilization are more important than broad managed-care trends.

Key Decisions for Investors

• Do not chase ACHC at current momentum levels; place a 1-3 month watch for a post-earnings entry only if operating cash flow tracks at least the midpoint of guidance and net leverage declines sequentially. Falsifier: higher legal reserves, cash conversion below plan, or EBITDA guidance maintained only through further capex cuts.
• Express relative provider preference through long THC / short ACHC in equal-dollar size over 3-6 months. The trade captures THC’s stronger estimate-revision profile while hedging healthcare-provider beta; exit if ACHC demonstrates two consecutive quarters of liability-cost stabilization and faster deleveraging than THC.
• For existing ACHC longs, trim into strength and retain a smaller 6-12 month core only if management quantifies litigation exposure and settlement/payment timing. A 15-20% pullback without a change in cash-flow guidance would offer a more favorable re-entry setup than adding after a sentiment-driven rerating.
• Prefer ENSG as the long-only post-acute growth exposure for 6-18 months, but size below benchmark until labor-cost trends and reimbursement-rate visibility are confirmed. Falsifier: occupancy or margin deceleration that prevents expected earnings growth from converting into free cash flow.